REG - Oxford Biomedica PLC - Director Dealings

Oxford BioMedicaAnnouncement

01/12/2020 12:20

RNS Number : 1314H
  
Oxford Biomedica PLC
  
01 December 2020
  
 

 
 
 
Director Dealings 
 
Oxford, UK - 01 December 2020: Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE: OXB a leading gene and cell therapy group, today announces that Dr. Andrew Heath, a Non-Executive Director of the Group, sold 28,597 ordinary shares of 50p each ("Ordinary Shares") in the Company on 30 November 2020 on the London Stock Exchange at a price of 869.2p.
 
15,756 Ordinary Shares were sold by Dr. Heath's wife (Eva Lackner) on 30 November 2020 on the London Stock Exchange at a price of 868.8p and are therefore considered a beneficial holding of Dr. Heath. 
 
Following these sales Dr. Andrew Heath holds 11,628 shares representing 0.01% of the Company.
 
The below notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail of the number of Ordinary Shares purchased.
 



 1.


Details of the person discharging material responsibilities/person closely                 associated
 




 a.


Name


 Dr. Andrew Heath
 




 2.


Reason for the notification
 




 a.


Position/status


 Non-Executive Director
 




 b.


Initial notification /amendment


 Initial notification
 




3.


Details of the issuer, emission allowance, market participant, auction platform, auctioneer or auction monitor
 




 a.


Name


 Oxford Biomedica plc
 




 b.


Legal Entity Identifier


 213800S1GVQNXQ15K851
 




4.


Details of the transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
 




 a.


Description of the financial instrument, type of instrument identification code


 Oxford Biomedica plc Ordinary Shares of 50p each
 
 
 GB00BDFBVT43
 




b.


Nature of the transaction


 Disposal of ordinary shares
 




c.


Currency


 GBP - British Pound
 
 




d.


Price(s) and volume(s)


 
Price(s)
 


 
Volume(s)




 


 


£8.69


28,597




e.


Aggregated information
·      Aggregated volume
·      Price
·      Aggregated total
 


 
28,597
 
 £8.6922
 £248,570.84
 




f.


Date of the transaction


 2020-11-30
 




g.


Place of the transaction


 London Stock Exchange, Main Market (XLON)
 



 
 



 1.


Details of the person discharging material responsibilities/person closely                 associated
 




 a.


Name


 Eva Lackner
 




 2.


Reason for the notification
 




 a.


Position/status


 Person closely associated with Dr. Andrew Heath, Non- Executive Director
 




 b.


Initial notification /amendment


 Initial notification
 




3.


Details of the issuer, emission allowance, market participant, auction platform, auctioneer or auction monitor
 




 a.


Name


 Oxford Biomedica plc
 




 b.


Legal Entity Identifier


 213800S1GVQNXQ15K851
 




4.


Details of the transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
 




 a.


Description of the financial instrument, type of instrument identification code


 Oxford Biomedica plc Ordinary Shares of 50p each
 
 
 GB00BDFBVT43
 




b.


Nature of the transaction


 Disposal of ordinary shares
 




c.


Currency


 GBP - British Pound
 




d.


Price(s) and volume(s)


 
Price(s)
 


 
Volume(s)




£8.69


15,756




e.


Aggregated information
·      Aggregated volume
·      Price
·      Aggregated total
 


 
 15,756
 
 £8.6883
 
 £136,892.85
 
 




f.


Date of the transaction


 2020-11-30
 




g.


Place of the transaction


 London Stock Exchange, Main Market (XLON)
 



 
 
The issued share capital of the Group is 82,294,468 ordinary 50p shares.
 
 
 
-Ends-
 



For further information, please contact:


 




 
Oxford Biomedica plc:
Natalie Walter, Company Secretary


 
Tel: +44 (0)1865 783 000



 
 
About Oxford Biomedica
 
Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, CNS disorders, liver diseases and respiratory disease. The Group has also entered into a number of partnerships, including with Novartis, Bristol Myers Squibb, Sanofi, Sio Gene Therapies, Orchard Therapeutics, Santen, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Additionally the group has signed a Clinical and Commercial Supply Agreement with AstraZeneca for manufacture of the adeno based COVID-19 vaccine candidate, AZN1222. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 550 people. Further information is available at www.oxb.com
 
 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
DSHMZMGZZMFGGZM